• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
ZHENG Yuting, HONG Tao, XU Kehui, WEN Minghao, YANG Jixue, WU Mengying, HANG Taijun, SONG Min. In vitro release of paclitaxel derivative liposome by paddle membrane binding assay[J]. Journal of China Pharmaceutical University, 2023, 54(6): 743-748. DOI: 10.11665/j.issn.1000-5048.2023041803
Citation: ZHENG Yuting, HONG Tao, XU Kehui, WEN Minghao, YANG Jixue, WU Mengying, HANG Taijun, SONG Min. In vitro release of paclitaxel derivative liposome by paddle membrane binding assay[J]. Journal of China Pharmaceutical University, 2023, 54(6): 743-748. DOI: 10.11665/j.issn.1000-5048.2023041803
shu

In vitro release of paclitaxel derivative liposome by paddle membrane binding assay

  • Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China

More Information
  • Received Date: April 17, 2023
  • Revised Date: December 05, 2023
    Graphical Abstract
    • Abstract
  • The in vitro release is an important index to evaluate the quality of liposome formulation.Currently, there is no evaluation method for the in vitro release of liposome in pharmacopoeia of various countries, which leads to the lack of unified standard and safety guarantee for the quality evaluation of liposome formulation.Taking the self-made paclitaxel derivative liposomes as an example, the paddle membrane binding method established by optimizing external release conditions was used to simulate the complete release of paclitaxel derivative drugs in 12 hours under physiological conditions.The results showed that using 0.5% SDS-HEPES as the release medium and a dialysis bag with a molecular weight cutoff of 1 000 kD to release the liposome solution met the requirements and had discrimination ability, providing a reference for the development of drug-loaded liposomes release methods in vitro.
    • FullText(HTML)
    • References (23)
  • [1]
    U.S. Food and Drug Administration. extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations[EB/OL]. (1997-09-01) [2023-03-27] https://www.fda.gov/regulatory-information/search-fda-guidance-documents/extended-release-oral-dosage-forms-development-evaluation-and-application-vitroin-in-vivo-correlations.
    [2]
    Bhardwaj U, Burgess DJ. A novel USP apparatus 4 based release testing method for dispersed systems[J]. Int J Pharm, 2010, 388(1/2): 287-294.
    [3]
    Liu Y, Zhang YJ, Wang ZY, et al. Research progress in bioanalysis and pharmacokinetics of liposome nanomedicine[J]. Acta Pharm Sin (药学学报), 2023, 58(4): 834-843.
    [4]
    Skoczen SL, Snapp KS, Crist RM, et al. Distinguishing pharmacokinetics of marketed nanomedicine formulations using a stable isotope tracer assay[J]. ACS Pharmacol Transl Sci, 2020, 3(3): 547-558.
    [5]
    Varache M, Ciancone M, Couffin AC. Optimization of a solid-phase extraction procedure for the analysis of drug-loaded lipid nanoparticles and its application to the determination of leakage and release profiles[J]. J Pharm Sci, 2020, 109(8): 2527-2535.
    [6]
    Xu XM, Khan MA, Burgess DJ. A two-stage reverse dialysis in vitro dissolution testing method for passive targeted liposomes[J]. Int J Pharm, 2012, 426(1/2): 211-218.
    [7]
    Magar KT, Boafo GF, Li XT, et al. Liposome-based delivery of biological drugs[J]. Chin Chem Lett (中国化学快报), 2022, 33(2): 587-596.
    [8]
    Wang S, Li WX, Sun KY, et al. Study of release kinetics and degradation thermodynamics of ferric citrate liposomes[J]. Chem Phys Lipids, 2019, 225: 104811.
    [9]
    Alavi S, Mahjoob MA, Haeri A, et al. Multivesicular liposomal depot system for sustained delivery of risperidone: development, characterization, and toxicity assessment[J]. Drug Dev Ind Pharm, 2021, 47(8): 1290-1301.
    [10]
    Tefas LR, Toma I, Sesarman A, et al. Co-delivery of gemcitabine and salinomycin in PEGylated liposomes for enhanced anticancer efficacy against colorectal cancer[J]. J Liposome Res, 2023, 33(3): 234-250.
    [11]
    Wang B, Xu QQ, Zhou CJ, et al. Liposomes co-loaded with ursolic acid and ginsenoside Rg3 in the treatment of hepatocellular carcinoma[J]. Acta Biochim Pol, 2021, 68(4): 711-715.
    [12]
    Hasan MM, Hamiduzzaman M, Jahan I, et al. Formulation development, characterization and In-vitro evaluation of tamoxifen loaded liposomes[J]. J Pharm Res Int, 2020,32(6): 64-82.
    [13]
    Shah H, Madni A, Khan MM, et al. pH-responsive liposomes of dioleoyl phosphatidylethanolamine and cholesteryl hemisuccinate for the enhanced anticancer efficacy of cisplatin[J]. Pharmaceutics, 2022, 14(1): 129.
    [14]
    Khan S, Madni A, Rahim MA, et al. Enhanced in vitro release and permeability of glibenclamide by proliposomes: development, characterization and histopathological evaluation[J]. J Drug Deliv Sci Technol, 2021, 63: 102450.
    [15]
    Modi S, Anderson BD. Determination of drug release kinetics from nanoparticles: overcoming pitfalls of the dynamic dialysis method[J]. Mol Pharm, 2013, 10(8): 3076-3089.
    [16]
    Dubatouka K, Agabekov V. Preparation and characterization of tissue plasminogen activator-loaded liposomes[J]. Soft Mater, 2022, 20(3): 358-363.
    [17]
    Wallace SJ, Li J, Nation RL, et al. Drug release from nanomedicines: selection of appropriate encapsulation and release methodology[J]. Drug Deliv Transl Res, 2012, 2(4): 284-292.
    [18]
    Regenold M, Steigenberger J, Siniscalchi E, et al. Determining critical parameters that influence in vitro performance characteristics of a thermosensitive liposome formulation of vinorelbine[J]. J Control Release, 2020, 328: 551-561.
    [19]
    O?uzhan Kaya H, Karpuz M, Nur Topkaya S. Electrochemical analysis of liposome-encapsulated colistimethate sodium[J]. Electroanalysis, 2022, 34(7): 1114-1120.
    [20]
    Yu YB, Huang YD, Feng WQ, et al. NIR-triggered upconversion nanoparticles@thermo-sensitive liposome hybrid theranostic nanoplatform for controlled drug delivery[J]. RSC Adv, 2021, 11(46): 29065-29072.
    [21]
    Heneweer C, Pe?ate Medina T, Tower R, et al. Acid-sphingomyelinase triggered fluorescently labeled sphingomyelin containing liposomes in tumor diagnosis after radiation-induced stress[J]. Int J Mol Sci, 2021, 22(8): 3864.
    [22]
    Janas C, Mast MP, Kirsamer L, et al. The dispersion releaser technology is an effective method for testing drug release from nanosized drug carriers[J]. Eur J Pharm Biopharm, 2017, 115: 73-83.
    [23]
    Wallenwein CM, Nova MV, Janas C, et al. A dialysis-based in vitro drug release assay to study dynamics of the drug-protein transfer of temoporfin liposomes[J]. Eur J Pharm Biopharm, 2019, 143: 44-50.
    • Related Articles

  • Related Articles

    [1]ZHANG Zhixing, DENG Hua, TANG Yun. Applications and challenges of artificial intelligence in the development of anticancer peptides[J]. Journal of China Pharmaceutical University, 2024, 55(3): 347-356. DOI: 10.11665/j.issn.1000-5048.2024040201
    [2]HU Zi’ang, GAO Liming, YU Wenying. Advances in the application of artificial intelligence in nucleic acid drug development[J]. Journal of China Pharmaceutical University, 2024, 55(3): 335-346. DOI: 10.11665/j.issn.1000-5048.2024033101
    [3]ZENG Hao, WU Guozhen, ZOU Wuxin, WANG Zhe, SONG Jianfei, SHI Hui, WANG Xiaojian, HOU Tingjun, DENG Yafeng. Optimization of Menin inhibitors based on artificial intelligence-driven molecular factory technology[J]. Journal of China Pharmaceutical University, 2024, 55(3): 326-334. DOI: 10.11665/j.issn.1000-5048.2024040904
    [4]TANG qian, CHEN Roufen, SHEN Zheyuan, CHI Xinglong, CHE Jinxin, DONG Xiaowu. Research progress of artificial intelligence-based small molecule generation models in drug discovery[J]. Journal of China Pharmaceutical University, 2024, 55(3): 295-305. DOI: 10.11665/j.issn.1000-5048.2024031501
    [5]XUE Feng, FENG Shuo, LI Jing. Application and prospect of artificial intelligence in antimicrobial peptides screening[J]. Journal of China Pharmaceutical University, 2023, 54(3): 314-322. DOI: 10.11665/j.issn.1000-5048.2023030901
    [6]GU Zhihao, GUO Wenhao, YAO Hequan, LI Xuanyi, LIN Kejiang. Research progress of the screening and generation of lead compounds based on artificial intelligence model[J]. Journal of China Pharmaceutical University, 2023, 54(3): 294-304. DOI: 10.11665/j.issn.1000-5048.2023042201
    [7]YU Zehao, ZHANG Leiming, ZHANG Mengna, DAI Zhiqi, PENG Chengbin, ZHENG Siming. Artificial intelligence-based drug development: current progress and future challenges[J]. Journal of China Pharmaceutical University, 2023, 54(3): 282-293. DOI: 10.11665/j.issn.1000-5048.2023041003
    [8]WANG Chao, XIAO Fu, LI Miaozhu, PAN Ying, DING Xiao, REN Feng, ZHAVORONKOV Alex, WANG Yazhou. Application progress of artificial intelligence in the screening and identification of drug targets[J]. Journal of China Pharmaceutical University, 2023, 54(3): 269-281. DOI: 10.11665/j.issn.1000-5048.2023041102
    [9]YAN Fangrong. Application and advance of artificial intelligence in biomedical field[J]. Journal of China Pharmaceutical University, 2023, 54(3): 263-268. DOI: 10.11665/j.issn.1000-5048.2023030304
    [10]Zhang Zunjian, Yu Shuqin, Xiang Bingren, An Dengkui. A New Artificial Neural Network Model:Combined Counter-Back Propagation and its Application[J]. Journal of China Pharmaceutical University, 1996, (11).

  • Cited by

    Periodical cited type(1)

    1. 赵倩，魏宇，郭凯敏，王文佳，周水平，孙鹤，方坚松，胡蕴慧. 人工智能结合生物网络对“养血清脑制剂”和“逍遥丸”组方的优化及验证. 中药药理与临床. 2024(04): 27-33 .

    Other cited types(3)

Catalog

    Get Citation
    PDF
    XML
    Article views (134) PDF downloads (242) Cited by(4)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：295209

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return